Vertex Pharmaceuticals Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $12.00B | $11.02B | $9.88B | $8.93B | $7.60B | $6.21B | $4.16B |
| Net Product Revenues | — | — | — | $9.87B | $8.92B | $7.57B | $6.20B | $4.00B |
| Collaborative and Royalty Revenues | — | — | — | $7.2M | $7.3M | $30.4M | $3.5M | $157.0M |
| Cost of Revenue | — | $1.65B | $1.53B | $1.26B | $1.08B | $904.2M | $736.3M | $547.8M |
| Gross Profit | — | $10.35B | $9.49B | $8.61B | $7.85B | $6.70B | $5.47B | $3.61B |
| Gross Margin | — | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | $3.05B | $1.83B | $1.75B |
| SG&A Expense | — | $1.75B | $1.46B | $1.14B | $944.7M | $840.1M | $770.5M | $658.5M |
| Operating Income | — | $4.17B | $-232.9M | $3.83B | $4.31B | $2.78B | $2.86B | $1.20B |
| Operating Margin | — | 34.8% | -2.1% | 38.8% | 48.2% | 36.6% | 46.0% | 28.8% |
| Interest Expense | — | — | — | — | — | — | $58.2M | $58.5M |
| Pretax Income | — | $4.64B | $248.5M | $4.38B | $4.23B | $2.73B | $3.12B | $1.39B |
| Income Tax Expense | — | $690.0M | $784.1M | $760.2M | $910.4M | $388.3M | $405.2M | $218.1M |
| Net Income | — | $3.95B | $-535.6M | $3.62B | $3.32B | $2.34B | $2.71B | $1.18B |
| Net Margin | — | 32.9% | -4.9% | 36.6% | 37.2% | 30.8% | 43.7% | 28.3% |
| EPS (Basic) | — | $15.46 | $-2.08 | $14.05 | $12.97 | $9.09 | $10.44 | $4.58 |
| EPS (Diluted) | — | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 |
| Shares Outstanding (Basic) | 254.0M | 255.7M | 257.9M | 257.7M | 256.1M | 257.7M | 259.8M | 256.7M |
| Shares Outstanding (Diluted) | 254.0M | 258.0M | 257.9M | 260.5M | 259.1M | 259.9M | 263.4M | 260.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |